Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab versus tacrolimus in primary membranous nephropathy
2020-003233-38Phase 3Active
- Sponsor
- Roche
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of obinutuzumab in idiopathic membranous glomerulonephritis (IMG) (2 arms), sponsored by Roche. Primary endpoint: Complete remission at Week 104. Started Dec 2020; status: active.
02
Drugs
obinutuzumab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on 2020-003233-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003233-38.